Chutes & Ladders: Interim CEO resigns from troubled Able Laboratories

Robert G. Mauro, the president and interim CEO of troubled Able Laboratories, has resigned. In a statement, Able announced: "The ongoing disruption in the company's operations caused by its product recall and the suspension of manufacturing activities has had, and will continue to have, a material adverse effect on the company's results of operations and financial position. Able can give no assurance as to if or when it will be able to resume manufacturing operations."

- read this press release for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.